AstraZeneca (Alexion)
About AstraZeneca (Alexion)
Alexion, AstraZeneca's rare-disease group, maintains a major UK presence developing complement-based therapies for ultra-rare disorders.
Leadership Team
Leadership as listed on alexion.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Products & Services
Products and services as listed on alexion.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Ultomiris
Alexion-listed medicine; generic name ravulizumab-cwvz.
Source: alexion.comStrensiq
Alexion-listed medicine; generic name asfotase alfa.
Source: alexion.comKanuma
Alexion-listed medicine; generic name sebelipase alfa.
Source: alexion.comKoselugo
Alexion-listed medicine; generic name selumetinib.
Source: alexion.comBeyonttra
Alexion-listed medicine; generic name acoramidis.
Source: alexion.comSites in Ireland
Dublin
One of two Alexion manufacturing facilities in Ireland; Ireland also hosts its global supply chain.
Source: alexion.comAthlone, Co. Westmeath
One of two Alexion manufacturing facilities in Ireland supporting global operations.
Source: alexion.comSites as listed on alexion.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Pipeline & Regulatory Record
What public registers list for Alexion, AstraZeneca Rare Disease (group figures): clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 10 Oct 2026.
Clinical trials 42 in our ClinicalTrials.gov registers · 2 in the EU register
| Study | Phase | Status |
|---|---|---|
| Study of ALXN2220 Versus Placebo in Adults With ATTR-CM NCT06183931 · site in Ireland · Transthyretin Amyloid Cardiomyopathy |
Phase 3 | Active, closed |
| An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy NCT07789483 · site in Ireland · Transthyretin Amyloid Cardiomyopathy (ATTR-CM) |
Phase 3 | Not yet open |
| Lysosomal Acid Lipase (LAL) Deficiency Registry NCT01633489 · site in Ireland · Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease |
Observational | Recruiting |
| Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data NCT07413250 · Paroxysmal Nocturnal Hemoglobinuria, PNH |
Observational | Active, closed |
| Long-term Safety of Danicopan: IPIG Registry-based Cohort Study NCT07413679 · Paroxysmal Nocturnal Hemoglobinuria, PNH |
Observational | Active, closed |
| Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation NCT06744647 · Antibody-Mediated Rejection, Kidney Transplantation |
Phase 2 | Active, closed |
| Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD NCT06724809 · NMOSD, Neuromyelitis Optica Spectrum Disorders |
Phase 3 | Active, closed |
| Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP NCT06079359 · Hypophosphatasia |
Phase 3 | Active, closed |
| Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa NCT06079372 · Hypophosphatasia |
Phase 3 | Active, closed |
| Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) NCT06291376 · Immunoglobulin A Nephropathy, IgAN |
Phase 3 | Active, closed |
Showing 10 of 42, trials with Irish sites first. The full lists are on the sponsor pages below.
All trials by sponsor name 1 registry name
Drugs in these trials 13 compounds
EU trials register (CTIS) 2 authorised or ongoing
- A Phase 1/2, Open-Label, Dose Finding Study to Investigate the Safety, Tolerability, and Efficacy of ALXN2350 Gene Therapy in Adult Participants with Symptomatic BAG3 Mutation-Associated Dilated Cardiomyopathy2024-519674-40-00 · Phase I/II · Ongoing
- OCTAGON:A Phase 4, Single Arm Study to Investigate Oral Corticosteroid Tapering in Adult Patients with Generalized Myasthenia Gravis Treated with Ravulizumab2025-522555-26-00 · Phase IV · Authorised
NICE technology appraisals 8 of its medicines · 8 current
- Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuriaNICE TA1010 · Optimised · 23 Oct 2024
- Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal)NICE TA961 · Terminated (no company submission) · 28 Mar 2024
- Ravulizumab for treating generalised myasthenia gravis (terminated appraisal)NICE TA940 · Terminated (no company submission) · 20 Dec 2023
- Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)NICE TA941 · Terminated (no company submission) · 20 Dec 2023
- Ravulizumab for treating atypical haemolytic uraemic syndromeNICE TA710 · Recommended · 23 Jun 2021
- Ravulizumab for treating paroxysmal nocturnal haemoglobinuriaNICE TA698 · Recommended · 19 May 2021
- Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal)NICE TA647 · Terminated (no company submission) · 2 Sep 2020
- Eculizumab for treating refractory myasthenia gravis (terminated appraisal)NICE TA636 · Terminated (no company submission) · 30 Jun 2020
Appraisals of medicines sold under a brand this company holds in EMA or FDA records, from our NICE appraisals register. NICE decisions apply to the NHS in England. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Group (Alexion, AstraZeneca Rare Disease): founded 1913, headquarters Cambridge Biomedical Campus, website astrazeneca.com. Wikidata Q731938 · Wikipedia. From Wikidata (CC0), matched by the group's SEC filer number.
How this is matched: register records are linked to this page by the organisation name they carry, here Alexion Pharmaceuticals, Inc.; Alexion Pharmaceuticals Inc.; Alexion Europe SAS; Alexion Europe S.A.S.; ALEXION PHARM; ALEXION PHARMS INC. Spot a wrong match? Tell us.
Financials & Irish Entities
From the annual reports AstraZeneca PLC files with the US Securities and Exchange Commission (20-F, IFRS), in USD as reported. Latest financial year: to Dec 2025.
| Year to | Revenue | R&D | R&D % | Net income | Filing |
|---|---|---|---|---|---|
| Dec 2025 | $58.74bn | $14.23bn | 24.2% | $10.23bn | 20-F 2026 |
| Dec 2024 | $54.07bn | $13.58bn | 25.1% | $7.04bn | 20-F 2026 |
| Dec 2023 | $45.81bn | $10.94bn | 23.9% | $5.96bn | 20-F 2026 |
| Dec 2022 | $44.35bn | $9.76bn | 22.0% | $3.29bn | 20-F 2025 |
| Dec 2021 | $37.42bn | $9.74bn | 26.0% | $112m | 20-F 2024 |
Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.
Companies registered in Ireland 4 active in the CRO register
| Company | CRO no. | Registered | Last accounts |
|---|---|---|---|
| Astrazeneca Pharmaceuticals (Ireland) Designated Activity Company DAC - Designated Activity Company (limited by shares) | 55502 | 1976 | Dec 2025 |
| Alexion Pharma Holding Limited LTD - Private Company Limited by Shares | 528477 | 2013 | Dec 2024 |
| Alexion Pharma International Operations Limited LTD - Private Company Limited by Shares | 528478 | 2013 | Dec 2024 |
| Astrazeneca Ireland Limited LTD - Private Company Limited by Shares | 734129 | 2023 | Dec 2024 |
From the Companies Registration Office (CRO Open Data, CC BY 4.0). A company is listed when GLEIF's legal entity register links it to AstraZeneca PLC as its ultimate parent, or when we checked its name and registered address by hand. Branches of foreign companies appear as "External company". Spot a missing or wrong entry? Tell us.
